retatrutide phase 2 nejm 2023 obesity trial jastreboff Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished nejm Semaglutide, a glucagon-like peptide-1

Research 2

Some are prescribed off-label by medical providers

This is where the marketing often gets ahead of the medicine

Jedn z najwikszych barier w dostpie do nowoczesnego leczenia otyoci w Polsce jest brak refundacji przez Narodowy Fundusz Zdrowia (NFZ)

- The spray contains BHA, AHA, tea tree oil, and centella asiatica

Generics to dramatically cut cost: experts Novo Nordisk the company behind blockbuster diabetes and weight-loss drugs Ozempic and Wegovy had for years held a patent on semaglutide, the active ingredient in those drugs that triggers the release of insulin and is used to treat diabetes and to aid weight loss